![Jean Bennett](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean Bennett
Director/Board Member at
AKOUOS
Net worth: 1 M $ as of 31/08/2026
Profile
Jean Bennett is the founder of Spark Therapeutics, Inc. (2013), Limelight Bio, Inc. (2017), GenSight Biologics, Inc. (2012), and Opus Genetics, Inc. (2021).
Titles held at Opus Genetics, Inc. included Director.
Current jobs included Director at SparingVision SAS since 2023, Director at Akouos, Inc. since 2018, Director at Retinal Degeneration Fund since 2022, Director at Center for Advanced Retinal & Ocular Therapies since 2014, Director-Data Safety Board at Genascence Corp.
since 2024, Director at AAVantgarde Bio Srl since 2022, Director at Opus Genetics, Inc. since 2024, Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the National Academy of Medicine (United States), Member of The Association for Research in Vision & Ophthalmology, Professor-Emeritus at Perelman School of Medicine since 2024, and Member of the American Society of Gene & Cell Therapy.
Former jobs include Director at Adverum Biotechnologies, Inc. and Independent Director at REGENXBIO, Inc. from 2021 to 2026.
Education includes undergraduate degree from Yale University, doctorate degrees from the University of California, Berkeley and Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OPUS GENETICS, INC. 0.31% | 20/04/2026 | 259,019 ( 0.31% ) | 937 649 $ | 31/08/2026 |
REGENXBIO, INC. 0.04% | 29/05/2026 | 28,861 ( 0.04% ) | 274 180 $ | 31/08/2026 |
Jean Bennett active positions
| Companies | Position | Start |
|---|---|---|
| OPUS GENETICS, INC. | Director/Board Member | 22/10/2024 |
| AKOUOS | Director/Board Member | 01/01/2018 |
National Academy of Medicine (United States)
 National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Corporate Officer/Principal | - |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services Operates as medical and professional organization that represents researchers and scientists devoted to the discovery | Corporate Officer/Principal | - |
Retinal Degeneration Fund
 Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Director/Board Member | 01/01/2022 |
Genascence Corp.
 Genascence Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing gene therapy products for prevalent musculoskeletal diseases | Corporate Officer/Principal | 01/01/2024 |
AAVantgarde Bio Srl
 AAVantgarde Bio Srl BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Director/Board Member | 01/01/2022 |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology Develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa | Director/Board Member | 01/01/2023 |
American Academy of Arts & Sciences
 American Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services Operates as organization which honours excellence and convenes leaders | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Former positions of Jean Bennett
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Jean Bennett
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
62
1st degree connections
22
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 22 |
|---|---|
REGENXBIO, Inc.
 REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Academy of Sciences
 National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services Operates as a private, nongovernmental institution that advises on issues related to science and technology | Commercial Services |
American Academy of Arts & Sciences
American Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services Operates as organization which honours excellence and convenes leaders | Commercial Services |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Commercial Services |
The Association for Research in Vision & Ophthalmology
 The Association for Research in Vision & Ophthalmology Miscellaneous Commercial ServicesCommercial Services Operates association for research in vision and ophthalmology | Commercial Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adverum Biotechnologies, Inc.
 Adverum Biotechnologies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company that develops gene therapies | Health Technology |
Perelman School of Medicine
 Perelman School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Develops therapy products for debilitating diseases | Health Technology |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services Operates as medical and professional organization that represents researchers and scientists devoted to the discovery | Commercial Services |
Limelight Bio, Inc.
 Limelight Bio, Inc. BiotechnologyHealth Technology Develops genetic therapies | Health Technology |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology Develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa | Health Technology |
Akouos, Inc.
 Akouos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a genetic medicine company that develops adeno-associated viral vector-based gene therapies for sensorineural hearing loss | Commercial Services |
Gensight Biologics, Inc.
 Gensight Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Gensight Biologics SA, Gensight Biologics, Inc. is a biopharmaceutical company specializing in developing gene therapies for severe inherited neurodegenerative diseases of the eye and central nervous system. The company is based in New York, NY. The company focuses on retinal disorders such as Leber hereditary optic neuropathy (LHON), retinitis pigmentosa (RP), and geographic atrophy in dry age-related macular degeneration (dry-AMD). It employs technologies including gene therapy, mitochondrial targeting sequences (MTS), and optogenetics to develop treatments aimed at preserving or restoring vision. The company’s proprietary MTS technology enables delivery of nuclear-encoded proteins into mitochondria to restore function impaired by genetic mutations, while its optogenetics approach involves transferring genes encoding light-sensitive proteins to retinal ganglion cells, combined with a wearable device to restore light responsiveness and vision. The company’s clinical pipeline includes product candidates like GS010 (lenadogene nolparvovec) and GS030. The company was founded by Jean Bennett. | Commercial Services |
Retinal Degeneration Fund
Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Miscellaneous |
Center For Advanced Retinal & Ocular Therapies | |
Ocuphire Pharma, Inc.
 Ocuphire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals for eye disorders | Health Technology |
Genascence Corp.
Genascence Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing gene therapy products for prevalent musculoskeletal diseases | Health Technology |
AAVantgarde Bio Srl
AAVantgarde Bio Srl BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Health Technology |
- Stock Market
- Insiders
- Jean Bennett
